Actionable news
0
All posts from Actionable news
Actionable news in ALNY: Alnylam Pharmaceuticals, Inc.,

BioPharmCatalyst new tool; Inotek ITEK fails Phase 2 glaucoma trial

Price and Volume Movers

The BioPharmCatalyst Biotech Stocks page has been created to track the Top 10 intra-day and end of day Gainers, Losers and stocks with high levels of Relative Volume. All financial data on BioPharmCatalyst is now updated throughout the day with delays of 15-35 minutes.

Inotek Pharmaceuticals Corporation (NASDAQ: ITEK) shares have plunged in the after-hours session following the failure of its Phase 2 trial of trabodenoson and latanoprost for the treatment of glaucoma. The company noted that after eight weeks of treatment no meaningful clinical advantage in intraocular pressure (IOP) reduction for the fixed dose combinations was observed. The company also announced that it is exploring its strategic alternatives as a result of the trial failure.

Ocular Therapeutix Inc (NASDAQ:OCUL) shares slid to close down 25% to $7.12. The downward move follows an article by STAT...


More